Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Breast Cancer (mBC) Clear all
Recruiting Not applicable Interventional

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

NCT04968964
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
DiviTum® TKa assay, Study Care Plans
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

NCT02659514
View directory record Official record
Conditions
Breast Cancer
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

STAR Cape+BKM120 MBC With Brain Met

NCT02000882
View directory record Official record
Conditions
Brain Metastases, Breast Cancer, Metastatic Breast Cancer
Interventions
BKM120, capecitabine, Trastuzumab
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Multiple Locations, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

NCT00928330
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

NCT01745367
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Tivozanib Hydrochloride, paclitaxel, Placebo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jul 24, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

NCT06855654
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Promoting Resilience in Women with Breast Cancer (PRISM)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

NCT00709761
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib/nab-Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
13
States / cities
La Verne, California • Long Beach, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

NCT00940225
View directory record Official record
Conditions
Solid Tumors, Cancer
Interventions
Cabozantinib, Placebo
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
34
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

NCT00570258
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, erlotinib, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
6
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Springdale, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

NCT03952325
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel, Nivolumab, Pembrolizumab, Atezolizumab
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 24, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

NCT07007559
View directory record Official record
Conditions
Breast Cancer, Metastatic
Interventions
Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

NCT00960960
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Pictilisib, Letrozole, Paclitaxel, Trastuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

NCT02229149
View directory record Official record
Conditions
Breast Neoplasms, Malignant Tumor of the Breast
Interventions
Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Multiple Locations, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 24, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
65 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
73
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

NCT01808573
View directory record Official record
Conditions
HER2+ Metastatic Breast Cancer (MBC)
Interventions
neratinib, capecitabine, lapatinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 24, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674
View directory record Official record
Conditions
Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions
Tucatinib, Eribulin, Trastuzumab
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Withdrawn Phase 2 Interventional

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

NCT05079360
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

NCT00320385
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
87
States / cities
Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Letrozole, Fulvestrant
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177
View directory record Official record
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Jul 24, 2026, 2:06 AM EDT
Completed No phase listed Observational

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

NCT01598597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

NCT02312622
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
Interventions
Pegylated Irinotecan
Drug
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 24, 2026, 2:06 AM EDT